Background {#Sec1}
==========

Viral hepatitis is the major cause of hepatitis \[[@CR1]\]. Among all types of viral hepatitis, hepatitis B virus (HBV) and hepatitis C virus (HCV) entail infections that are known for engendering chronic liver inflammation and hepatic malignancy \[[@CR2]\]. In addition to HBV or HCV monoinfection, HBV/HCV coinfection has been shown to be associated with an increased risk of disease progression and malignancy \[[@CR3]\]. Moreover, it has been reported that hepatic inflammation plays a major role in HBV- or HCV-induced liver damage, and immune cells including CD8(+)T lymphocytes as well as proinflammatory cytokines are also involved in this damage \[[@CR4]\]. Although hepatic inflammation is a symptom of HBV and HCV infection, the inflammatory response could be systemic, because of the immune reaction induced by the translocation of microbial products. \[[@CR5]\]. Research has shown that HBV can replicate in neuronal cells, which may account for the neuropathy associated HBV infection \[[@CR6]\]. Furthermore, HCV-infected microglia cells and astrocyte are detected in the brain, indicating biological basis of neurocognitive abnormalities in HCV infection \[[@CR7]\]. Recently, four independent studies indicate that viral hepatitis is associated with subsequent Parkinson disease \[[@CR8]--[@CR11]\]. These papers raised a specific aspect of viral hepatitis, but whether this reflects shared disease mechanisms in genetic or environmental susceptibility, or sequelae of viral hepatitis per se, or a consequence of treatment remains to be determined. It is of great interest to note that the association between viral hepatitis and psychiatric diseases has not been explored yet. We therefore aimed to investigate the association between viral hepatitis and bipolar disorder.

Bipolar disorder (BD), a type of psychiatric mood disorder, is manifested by chronic and recurrent mood fluctuations and involves a spectrum of symptoms including depressive, hypomanic, and manic manifestations \[[@CR12]\]. In the BD population, all-cause and suicide mortality rates are substantially approximately 2-fold and 10-fold higher, respectively, than those in the general population \[[@CR13]\]. Osby et al. further reported that the increased death rate in patients with BD is partly attributable to various potentially life-threatening medical comorbidities, particularly cardiovascular diseases \[[@CR14]\]. In a review of the evidence, Rege and Hopkinson suggest that systemic inflammation and neuroinflammation may be involved in the pathogenesis of BD \[[@CR15]\]. Inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and soluble tumor necrosis factor receptor type 1 have been reported to be involved in the inflammatory state \[[@CR16]\]. Another hypothesis of the association between medical conditions and subsequent BD was through inflammatory process, such as rheumatoid arthritis \[[@CR17]\], peptic ulcer disease \[[@CR18]\], and gastro-esophageal reflux disease \[[@CR19]\]. As there is a high prevalence of HBV or HCV infection in Taiwan, we are therefore interested in investigating whether chronic HBV or HCV infection is a risk factor for the development of BD.

In treatment of hepatitis, interferon-α, one of the treatment of HBV and HCV, was reported having neuropsychiatric side-effects \[[@CR20]\]. Also, in the treatment of chronic HCV infection, combination of interferon and ribavirin was reported having psychiatric adverse events, including major depression \[[@CR21]\]. Additionally, a study conducted by Quarantini and colleagues demonstrated that patients with HCV infection exhibit cognitive impairment, especially over visuo-spatial memory performance, which may be specific to HCV infection rather than secondary psychiatric comorbidities \[[@CR22]\]. Even though a case report demonstrated interferon therapy could induce mania \[[@CR23]\], limited evidence investigated the association between HBV/HCV and subsequent BD. To test these hypothesis that HBV or HCV infection is associated with subsequent BD, we conducted a nationwide, population-based cohort study to investigate whether HBV or HCV infection increases the risk of BD.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

The study was conducted using data from the Longitudinal Health Insurance Database (LHID), a data set comprising the claims data of people enrolled in the Taiwan National Health Insurance (NHI) program. The National Health Research Institutes (NHRI) randomly selected 1 million insured people from 1996 to 2000 and followed them. According to the NHRI report, the demographic characteristics showed no difference between the people in the LHID and those enrolled in the NHI program. The claims data in the LHID include a beneficiary registry, inpatient and outpatient files, and other medical services. All patient histories were collected from inpatient and outpatient files and recorded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The NHRI released the database with anonymous patient identification numbers to protect the privacy of the insured people.

Study population {#Sec4}
----------------

This was a retrospective, population-based cohort study, and we included a cohort of hepatitis patients and a comparison cohort to observe the occurrence of BD. The hepatitis cohort comprised patients with new onset HBV (ICD-9-CM 070.20 Viral hepatitis B with hepatic coma, acute or unspecified, without mention of hepatitis delta; 070.22 Viral hepatitis B with hepatic coma, chronic, without mention of hepatitis delta; 070.30 Viral hepatitis B without mention of hepatic coma, acute or unspecified, without mention of hepatitis delta; 070.32 Viral hepatitis B without mention of hepatic coma, chronic, without mention of hepatitis delta, and V02.61 Hepatitis B carrier) or HCV (ICD-9-CM 070.41 Acute hepatitis C with hepatic coma; 070.44 Chronic hepatitis C with hepatic coma; 070.51 Acute hepatitis C without mention of hepatic coma; 070.54 Chronic hepatitis C without mention of hepatic coma, and V02.62 Hepatitis B carrier) from January 1, 2000 to December 31, 2010. The date of first diagnosis of hepatitis was defined as the index date. The comparison cohort contained patients in the LHID without a diagnosis of hepatitis. Each patient in the hepatitis cohort was randomly frequency-matched with 4 controls according to various criteria including age (per 5 years) and sex. For the index date of the comparison cohort, patients were assigned the same date as those of the matched cases. Both cohorts excluded patients without complete characteristic data and aged younger than 20 years or those with a history of BD before the index date. In addition, considering the undiagnosed mood symptoms, we also excluded the patients having depression (ICD-9-CM 296.2 Major depressive disorder, single episode; 296.3 Major depressive disorder, recurrent episode; 311 Depressive disorder, not elsewhere classified) before the index date. Moreover, HBV/HCV can be contracted during sex \[[@CR24]\] and unsafe drug use \[[@CR25]\]. Hence, before the index date, we excluded patients having the diagnosis of borderline personality disorder (ICD-9-CM 301.83 Borderline personality disorder), which has been associated with risky sexual behaviors (no using condoms with changed partners) and substance use problems \[[@CR26]\], and we also excluded the patients having opioid dependence (ICD-9-CM 305.5 opioid abuse; 304.0 opioid type dependence). It has been suggested that the exclusion of these patients could decrease the selection bias. We followed these 2 cohorts until withdrawal from the insurance program, BD occurrence (ICD-9-CM 296 Episodic mood disorders), or December 31, 2011. The confounding factors in this study were age, sex, and BD-associated comorbidities. Sex difference was noted among hepatitis infection and may influence the outcome \[[@CR27]\]. Patients with comorbidities were defined as those with a history of comorbidities before the index date. The BD-associated comorbidities in this study included cirrhosis (ICD-9-CM 571.2 571.2 Alcoholic cirrhosis of liver; 571.5 Cirrhosis of liver without mention of alcohol; 571.6 Biliary cirrhosis), hypertension (ICD-9-CM 401-405 Hypertensive disease), hyperlipidemia (ICD-9-CM 272 Disorders of lipoid metabolism), asthma (ICD-9-CM 493 Asthma), coronary artery disease (CAD, ICD-9-CM 410-414 Ischemic heart disease), alcohol-related disorder (ALD, ICD-9-CM 291 Alcohol-induced mental disorders; 303 Alcohol dependence syndrome; 305.0 Alcohol abuse; 571.0 Alcoholic fatty liver; 571.1 Acute alcoholic hepatitis; 571.3 Alcoholic liver damage, unspecified; 790.3 Excessive blood level of alcohol; A215, and V11.3 Alcoholism), anxiety \[[@CR28]\] (ICD-9-CM 300.00 Anxiety state, unspecified). Additionally, we listed major depressive disorder (ICD-9-CM 296.20 Major depressive disorder, single episode; 296.30 Major depressive disorder, recurrent episode; 311 Depressive disorder, not elsewhere classified) for further adjustment because there were overlapping symptoms between unipolar depression and bipolar depression \[[@CR29]\].

Statistical analyses {#Sec5}
--------------------

In this study, the demographic characteristics and medical records in LHID included continuous data (such as age) and binary variables (such as sex, treatment status and comorbidity). They were all in reasonable range. The characteristics of the study population, which were represented by their age, sex, and comorbidities, were described using mean and percentage values. To examine the difference between the hepatitis and comparison cohorts, we used a *t* test to analyze age and a Chi square test to analyze sex and comorbidities. Furthermore, we calculated the incidence density of subsequent BD in both cohorts. The cumulative incidence curves for the 2 cohorts were evaluated using the Kaplan--Meier method. The log-rank test was used to test the difference between the incidence curves. To measure the risk of BD in the hepatitis cohort compared with the comparison cohort, we transformed all categorical variables into dummy variables and evaluated crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) by using Cox proportional hazard models. We also analyzed the risk of BD stratified by age, sex, and comorbidities. We used SAS Version 9.4 software (SAS Institute, Cary, NC, USA) to manage the data and conduct the statistical analyses. The incidence curves were plotted using R software (R Foundation for Statistical computing, Vienna, Austria). A 2-sided p \< .05 reached the level of significance.

Results {#Sec6}
=======

We selected a total of 48,215 patients with hepatitis in this study. As shown in Table [1](#Tab1){ref-type="table"}, the types of hepatitis were HBV infection (71.5%), HCV infection (20.5%), and HBV/HCV coinfection (8.0%). The mean age of the hepatitis and comparison cohorts was approximately 46 years (SD: 15), and the male patients constituted the highest proportion (57.1%) of the patients in these cohorts. The proportions of comorbidities in the hepatitis cohort were significantly greater than those in the comparison cohort (all p \< .001) (Table [1](#Tab1){ref-type="table"}).Table 1Distribution of age, gender, and comorbidity between hepatitis infection and comparison cohortHepatitis infectionComparison N = 192,860p value^†^Total (n = 48,215)HBV (n = 34,459, 71.5%)HCV (n = 9893, 20.5%)Both (n = 3863, 8.0%)N%N%N%N%N%Age, year0.99 20--3412,79926.611,02832.0112111.365016.851,19626.6 35--4916,56834.413,02337.8234723.7119831.066,27234.4 50--6412,01324.9744721.6331933.6124732.348,05224.9 65+683514.229618.59310631.476819.927,34014.2 Mean (SD)46.5(15.4)43.4(14.2)55.8(15.6)51.0(15.0)46.3(15.8)0.001Gender0.99 Women20,69942.914,13441.0486349.2170244.182,79642.9 Men27,51657.120,32559.0503050.8216155.9110,06457.1Comorbidity Cirrhosis28,45059.018,80354.6690569.8274271.023,11112.0\< 0.001 Hypertension12,54226.0687620.0433143.8133534.641,37921.5\< 0.001 Hyperlipidemia967120.1627618.2250125.389423.127,68114.4\< 0.001 Asthma30266.2818005.229269.363007.7791144.73\< 0.001 CAD601612.531079.02225322.865617.018,8759.79\< 0.001 ALD32166.6719565.689269.363348.6553042.75\< 0.001 Anxiety34007.0520816.049769.873438.8884074.36\< 0.001 MDD16153.359672.814644.691844.7639172.03\< 0.001Chi square test*CAD* coronary artery disease, *ALD* alcohol-related disorder, *MDD* major depressive disorders, *SD* standard deviation^†^Total hepatitis infection versus comparison

We observed 136 and 58 BD occurrences in the comparison and hepatitis cohorts, respectively (Table [2](#Tab2){ref-type="table"}). The incidence of BD in the comparison cohort was 1.14 per 10,000 person-years, whereas that in the hepatitis cohort was 2.04 per 10,000 person-years. Moreover, the incidence rates of BD were 1.79, 2.23, and 3.62 per 10,000 person-years in the HBV, HCV, and coinfection groups, respectively (Table [2](#Tab2){ref-type="table"}). Figure [1](#Fig1){ref-type="fig"} shows that the incidence curves for BD in the hepatitis cohort were significantly higher than those in the comparison cohort (log-rank test p \< .001). After adjustment for BD-associated risk factors, patients with coinfection of HBV and HCV exhibited a significantly increased risk of BD compared with those in the comparison group (adjusted HR 2.16, 95% CI 1.06--4.41; p \< .001) (Table [2](#Tab2){ref-type="table"}). The results revealed a significantly higher risk for BD inpatients younger than 65 years old, female patients, and patients with the comorbidities of anxiety and major depressive disorder. We noted significantly lower risk for subsequent BD was the comorbidity of hyperlipidemia. In addition, we noted a study, conducted by Ayano et al. \[[@CR27]\], showing sex difference among hepatitis infection, and having influence on the outcome. Hence, sex was a confounding factor in our study and we adjusted it in our study. Table 2Estimation of bipolar Incidence and hazard ratio by Cox proportional hazard modelsEvent noPY%HR (95% CI)CrudeAdjustedHepatitis infection None1361,188,0371.141.001.00 All58284,8952.041.78 (1.31, 2.41)\*\*\*1.38 (0.96, 1.98) HBV37206,3321.791.56 (1.09, 2.25)\*1.27 (0.85, 1.90) HCV1253,7062.231.93 (1.07, 3.48)\*1.38 (0.73, 2.60) Both924,8573.623.22 (1.64, 6.32)\*\*\*2.16 (1.06, 4.41)\*Age, year 20--49125951,5751.311.85 (1.04, 3.27)\*2.54 (1.34, 4.82)\*\* 50--6456346,8851.612.22 (1.21, 4.06)\*\*2.51 (1.35, 4.67)\*\* 65+13174,4720.751.001.00Gender Women104635,8361.641.53 (1.15, 2.02)\*\*1.37 (1.03, 1.83)\* Men90837,0961.081.001.00Comorbidity Cirrhosis  No1351,168,0921.161.001.00  Yes59304,8401.941.66 (1.22, 2.26)\*\*1.23 (0.84, 1.80) Hypertension  No1511,177,3421.281.001.00  Yes43295,5901.451.10 (0.79, 1.55)1.05 (0.69,1 .60) Hyperlipidemia  No1711,265,0961.351.001.00  Yes23207,8371.110.80 (0.52, 1.23)0.54 (0.33, 0.87)\* Asthma  No1811,410,5131.281.001.00  Yes1362,4192.081.55 (0.88, 2.72)1.24 (0.69, 2.22) CAD  No1701,337,5811.271.001.00  Yes24135,3521.771.36 (0.89, 2.08)1.13 (0.68, 1.88) ALD  No1851,434,6211.291.001.00  Yes938,3112.351.71 (0.87, 3.34)1.11 (0.56, 2.21) Anxiety  No1651,415,6521.171.001.00  Yes2957,2805.064.08 (2.75, 6.06)\*\*\*1.80 (1.15, 2.83)\* Major depressive disorders  No1471,445,0191.021.001.00  Yes4727,91316.815.8 (11.4, 22.0)\*\*\*12.9 (8.85, 18.7)\*\*\*Multivariable analysis including age, sex, and comorbidities of cirrhosis, hypertension, hyperlipidemia, asthma, CAD, ALD, anxiety and major depressive disorders*PY* person-years,  *%* Rate, per 10,000 person-years, *CAD* coronary artery disease, *ALD* alcohol-related disorder\* p \< 0.05, \*\* p  \< 0.01, \*\*\* p \< 0.001 Fig. 1Cumulative incidence of bipolar disorders in patients with different hepatitis infection

Table [3](#Tab3){ref-type="table"} presents the risk for BD stratified by age, sex, comorbidity, and types of hepatitis. Comparing the hepatitis cohort with the comparison cohort revealed that the HRs of BD significantly increased in patients aged more than 65 years (HR 4.49, 95% CI 1.25--16.2). Compared with the control group, a significantly increased risk for BD was observed in the female (HR 1.70, 95% CI 1.06--2.75) patients in the hepatitis group. In the HBV group, an increased risk of subsequent BD was noted among female patients (HR 1.87, 95% CI 1.13--3.10). In the HCV group, no association with the increased risk of subsequent BD was shown regardless of age, gender, and comorbidity. In both the HBV and HCV groups, an increased risk of subsequent BD was noted among patients aged more than 65 years (HR 16.3, 95% CI 2.83--93.5), and patients having any comorbidity (HR 2.28, 95% CI 1.09--4.76). In Table [2](#Tab2){ref-type="table"}, crude HRs were the results of simple Cox regression, and adjusted HRs were the results of multiple Cox regression with fully adjustment. Table [3](#Tab3){ref-type="table"} shows the results of stratified analysis. We stratified by sub groups of each covariate, and calculated the HRs. Table [3](#Tab3){ref-type="table"} shows the results of stratified analysis. We stratified by sub groups of each covariate, and calculated the HRs. We have further modified Table [3](#Tab3){ref-type="table"}. The adjusted HRs in total subjects (n = 48,215), HBV (n = 34,459), HCV (n = 9893) and Both HBV/HCV (n = 3863) compared with Comparison group (n = 192,860).Table 3Incidence and hazard ratio for bipolar disorders stratified by age, gender and comorbidityComparison\
N = 192,860Hepatitis infectionTotal (n = 48,215)HBV (n = 34,459)HCV (n = 9893)Both (n = 3863)Event no%Event no%HR^†^ (95% CI)Event no%HR^†^ (95% CI)Event no%HR^†^ (95% CI)Event no%HR^†^ (95% CI)Age, year 20--49871.14382.011.35 (0.86, 2.11)281.811.30 (0.80, 2.10)52.281.17 (0.45, 3.03)53.832.19 (0.85, 5.62) 50--64411.45152.301.04 (0.53, 2.05)82.050.98 (0.43, 2.21)52.721.19 (0.44, 3.21)22.581.02 (0.24, 4.46) 65+80.5651.644.49 (1.25, 16.2)\*10.772.12 (0.25, 17.7)21.494.58 (0.83, 25.4)24.9516.3 (2.83, 93.5)\*\*Gender Women731.43312.491.70 (1.06, 2.75)\*242.801.87 (1.13, 3.10)\*41.471.02 (0.35, 2.92)32.631.80 (0.54, 5.94) Men630.93271.681.09 (0.65, 1.85)131.080.76 (0.39, 1.46)83.021.71 (0.77, 3.79)64.462.42 (0.99, 5.96)Comorbidity None690.88131.621.74 (0.96, 3.15)111.631.74 (0.92, 3.31)11.221.29 (0.18, 9.30)12.382.54 (0.35, 18.3) With any one671.66452.201.19 (0.81, 1.76)261.870.95 (0.59, 1.52)112.421.46 (0.77, 2.77)83.872.28 (1.09, 4.76)\*%: Rate, per 10,000 person-years\* p \< 0.05, \*\* p \< 0.01, \*\*\* p \< 0.001^†^ Multivariable analysis including age, sex, and comorbidities of cirrhosis, hypertension, hyperlipidemia, asthma, coronary artery disease, alcohol-related illness, anxiety, and major depressive disorders

In Table [4](#Tab4){ref-type="table"}, we demonstrated the association between antiviral drugs for hepatitis and the incidence of BD, revealing no association between antiviral drugs and increased risk of subsequent BD. We demonstrated the association between antiviral drugs for hepatitis and the incidence of BD, revealing no association between antiviral drugs and increased risk of subsequent BD. In Table [3](#Tab3){ref-type="table"}, it shows incidence, and hazard ratio of bipolar disorders between patients with hepatitis infection with and without treatment (with propensity score matching). Table [4](#Tab4){ref-type="table"} shows estimation of bipolar hazard ratio by simple and multiple Cox proportional hazard models (with propensity score matching).Table 4Incidence, and hazard ratio of bipolar disorders between patients with hepatitis infection with and without treatmentVariablesNEventPY%Crude HR (95% CI)Adjusted HR† (95% CI)Hepatitis infection Without treatment44,46154262,8192.051.001.00Only HBV treatment Lamivudine, telbivudine, adefovir, tenofovir, and entecavir2151211,8201.690.82 (0.20, 3.36)0.85 (0.21, 3.53)Only HCV treatment Ribavirin, interferon1081266233.021.48 (0.36, 6.05)1.29 (0.31, 5.37)Both HBV&HCV treatment522036340.00----*PY* Person-years,  *%* rate, per 10,000 person-years^†^ Multivariable analysis including age, sex, and comorbidities of cirrhosis, hypertension, hyperlipidemia, asthma, coronary artery disease, alcohol-related illness, anxiety, and major depressive disorders

Discussion {#Sec7}
----------

### Key findings {#Sec8}

In this study, we demonstrated that HBV or HCV infection may be associated with subsequent BD, and, to the best of our knowledge, we demonstrated their correlation for the first time by using a matched population-based cohort and 10-year follow-up period. The major findings of our study suggest a higher incidence of subsequent BD among patients with HBV/HCV coinfection. Also, we demonstrated the comorbidities related to the subsequent occurrence of BD, including hyperlipidemia, anxiety, and major depressive disorder. Anxiety was frequently comorbid with BD \[[@CR28]\]. Patients with major depression may have unrecognized BD \[[@CR30]\], and depressive symptoms were noted among the course of BD \[[@CR31]\]. On the other hand, evidence showed patients with chronic hepatitis B and C had psychosocially impaired their mental health and daily life \[[@CR32]\]. As a result, those conditions were associated with subsequent occurrence of BD. In addition, we noted hyperlipidemia had decreased risk for subsequent BD. We considered this may be associated with selection bias in our study. Mood stabilizer and atypical antipsychotics were used for the treatment of BD \[[@CR33]\]. The metabolic syndrome, including hyperlipidemia, was reported as the adverse effect of the treatment \[[@CR34]\]. As a result, patients with BD under those drugs treatment may have improved clinical condition but have the adverse effect of hyperlipidemia.

We noted that female patient with HBV infection was associated with the subsequent occurrence of BD. To the best of our knowledge, we hypothesized that the mechanism was possibly related to the interaction between sex hormone and the disease activity of HBV infection. Evidence shows that HBV infection is characterized by its lifelong persistence and inflammation \[[@CR35]\]. In addition, acute liver failure (ALF) was noted to be among the courses of chronic liver inflammation \[[@CR36]\]. Moreover, proinflammatory cytokines such as TNF-α may affect the brain by impairing the permeability of the blood brain barrier and neuroinflammation, particularly under the condition of ALF \[[@CR37], [@CR38]\]. In addition, studies have revealed that inflammation in the brain was associated with developing mood disorders, including BD, and that TNF-α was a critical cytokine in pathophysiology \[[@CR39]--[@CR41]\]. On the other hand, one study showed that sex hormones were associated with the disease activity of HBV infections \[[@CR42]\]. Although estrogen was reported to have a protective effect on the progression of HBV infection \[[@CR43]\], estrogen receptor gene polymorphisms in a Chinese population may be associated with occurrences of ALF \[[@CR44]\]. As a result, female patients with HBV demonstrate an increased risk of subsequent BD.

It has been shown elsewhere that the anti-HCV treatment (ribavirin and interferon) are related to the development of depression \[[@CR21]\]. In our study, we demonstrated the association between HBV/HCV and subsequent BD. When we further control the effects of anti-viral treatments to HBV or HCV infections (anti-HBV treatment: lamivudine, telbivudine, adefovir, tenofovir, and entecavir or anti-HCV treatment: ribavirin, interferon), we found no association between HBV or HCV treatment and increased risk of subsequent BD (Table [4](#Tab4){ref-type="table"}). Hence, we considered the association between HBV/HCV and subsequent BD may be attributed to the HBV/HCV infection/inflammation itself rather than the effect of treatment. However, future mechanistic studies are warranted.

In addition, our statistically matched study, including age, gender, and comorbidity, demonstrated increased risk of subsequent BD in patients having concurrent HBV and HCV infections. Our results reveal that this condition was associated with patients aged more than 65 years and having any comorbidity. HBV and HCV have been reported to be associated with CNS involvement through neuroinflammation \[[@CR37], [@CR45]\]. HBV/HCV coinfection is prone to involve more advanced and progressive liver damage than does monoinfection \[[@CR46]\]. Although treatment for HCV dominance in HBV/HCV coinfection can achieve HCV clearance, HBV reactivation has been noted \[[@CR3], [@CR47]\]. The reactivation of HBV could induce immune-mediated inflammatory reactions \[[@CR48], [@CR49]\], which are superimposed with the underlying chronic inflammation associated with HBV and HCV conditions. Hence, the inflammatory process was augmented, consequently increasing the risk of BD. In addition, the aforementioned studies have indicated that the ALF of HBV infection could impair the integrity of the blood--brain barrier \[[@CR37], [@CR38]\], and HCV could infect brain endothelial cells \[[@CR50]\], induce microglial activation \[[@CR51]\], and adversely interact with brain astrocytes \[[@CR52]\]. We suppose that the adverse influence of HBV and HCV cause the brain to be more vulnerable to neuroinflammation and HCV replication. Hence, the risk of BD increased more in HBV/HCV coinfection than in HBV or HCV infection. On the other hand, studies had shown the association between aging and neuroinflammation \[[@CR53]\], and we considered this condition may make elder patients with HBV/HCV coinfection more vulnerable to subsequent BD \[[@CR54]\]. Hence, we suppose that in patients with HBV/HCV coinfection, those aged more than 65 years may raise further concern about the increased risk of subsequent BD. Moreover, HCV was reported having comorbidities involving in systemic inflammation \[[@CR55], [@CR56]\] and may therefore increase the risk of subsequent BD.

### Limitations {#Sec9}

To the best of our knowledge, this is the first population-based study designed to investigate the association between viral hepatitis and BD. We employed a matched case--control design and a population-based cohort of patients with viral hepatitis and adequate controls as well as a sufficient number of comorbidities, thus further strengthening the study. However, limitations inherent to the use of claims databases were encountered. First, the diagnosis of hepatitis in the NHIRD was based on ICD-9-CM codes; therefore, the severity of hepatitis as a risk factor for developing BD was not explored. Also, we mark the temporal association by the chronological order, so we could not confirm the effect or the causal relationship between hepatitis infection and BD. Additionally, considering the possibility of reactivation, we included hepatitis carrier, ICD-9-CM codes of V02.61 and V02.62, in our study, and this management could affect the result revealed in our study. Nevertheless, in our study design, we conducted a 10-year follow-up to observe the long-term influence of HBV or HCV infection on the subsequent development of BD. Second, the association was evaluated according to the chronological order in which these two diseases were diagnosed. Whether the patients previously had BD-related symptoms without being diagnosed with BD was unknown. Third, information on numerous demographic variables, including socioeconomic status and family history, was unavailable; such information may provide useful data regarding factors associated with viral hepatitis and BD. Forth, BD was reported having early presentation in lifetime prevalence \[[@CR57]\]. Excluding patients younger than 20 years old in this study may limit the application. However, studies had shown that attention deficit hyperactivity disorder was often comorbid and easily confused with BD in younger age \[[@CR58]\]. Therefore, our study used more than 20 years old instead and demonstrated on the long-term relationship between HBV/HCV and BD. Furthermore, some immune-related diseases, such as rheumatoid arthritis \[[@CR17]\], were reported having association with subsequent BD. Hence, those diseases could be confounding factors. On the other hand, exclusion of depression and anxiety may have influence on the diagnosis of BD, and therefore influence the generalizability of our study. Forth, although our study sample comprised an adequate number of patients in the HBV/HCV and control groups as well as an adequate number of comorbidities, our findings were demonstrated only in this studied population; we could not validate the generalizability of the results to other populations. Finally, although we also provided the propensity score matching for hepatitis versus no-hepatitis patients (Additional file [1](#MOESM1){ref-type="media"}: Tables S1 and S2), there is no significance for the casual relationship of viral hepatitis and BDs, it may be due to the reason that if we deliberately adjust the control cohort for hypertension, hyperlipidemia, asthma, CAD, ALD, anxiety and MDD, then we may overlook the true risk for BDs in HBV, HCV or HBV/HCV patients, because the new control cohort consists of subjects with relatively higher risk. Due to the association between viral hepatitis and BDs, and the significant role of neuronal dysfunction are strongly suggested in BDs, we also plan to confirm the causal relationship of viral hepatitis and BDs, and the underlying mechanisms by using the human induced pluripotent stem cells from HBV/HCV patients and differentiated the neurons that are responsible for the phenotype of BD \[[@CR59]\].

Conclusions {#Sec10}
===========

The findings suggest that HBV/HCV infection may be associated with increased risk of subsequent BD. Additional prospective clinical and basic studies on the relationship between hepatitis and BD are warranted.
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===============

 {#Sec11}

**Additional file 1: Table S1.** Distribution of age, gender, and comorbidity between hepatitis infection and comparison cohort with propensity score matching. **Table S2.** Estimation of bipolar Incidence and hazard ratio by Cox proportional hazard models with propensity score matching.

ALF

:   Acute liver failure

BD

:   Bipolar disorder

CIs

:   Confidence intervals

HRs

:   Hazard ratios

HBV

:   Hepatitis B virus

HCV

:   Hepatitis C virus

ICD-9-CM

:   International Classification of Diseases, Ninth Revision, Clinical Modification

IRB

:   Institutional Review Board

LHID

:   Longitudinal Health Insurance Database

NHI

:   National Health Insurance

NHRI

:   National Health Research Institutes

**Electronic supplementary material**

The online version of this article (10.1186/s12967-018-1542-3) contains supplementary material, which is available to authorized users.

Lee-Won Chong, Chih-Chao Hsu and Chang-Yin Lee contributed equally to this work

Conception/Design: YCH; Provision of study materials: KHC, YCH; Collection and/or assembly of data: all authors; Data analysis and interpretation: all authors; Manuscript writing: LWC, YCH. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

Not applicable.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and materials {#FPar3}
==================================

Data are available from the NHIRD published by Taiwan National Health Insurance Bureau. Due to legal restrictions imposed by the Government of Taiwan in relation to the 'Personal Information Protection Act', data cannot be made publicly available. Requests for data can be sent as a formal proposal to the NHIRD (<http://nhird.nhri.org.tw>).

Consent for publication {#FPar4}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar5}
==========================================

This article does not contain any studies with human participants or animals performed by any of the authors. The NHIRD contains only encrypted patient information, it provides anonymous identification numbers and corresponding claims information, including gender, date of birth, administered medical services, and prescriptions given. Patient consent is not required to access the data stored in NHIRD. This study was approved by the Institutional Review Board (IRB) of China Medical University Hospital (CMUH104-REC2-115). The IRB waived the consent requirement.

Funding {#FPar6}
=======

This study was supported by Ministry of Science and Technology \[Grant Number: MOST 103-2314-B-715- 001-MY2, MOST 104-2314-B-715-003-MY3, MOST 105-2320-B-039-059-MY3, and MOST 105-2634-F-039-001\] and Mackay Medical College \[Grant Number: RD1050179\], Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence \[Grant Number: MOHW105-TDU-B-212-133019\], China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project \[Grant Number: BM10501010037\], NRPB Stroke Clinical Trial Consortium (MOHW107-TDU-B-212-123004), China Medical University Hospital, Academia Sinica Stroke Biosignature Project (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005-), Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Publisher's Note {#FPar8}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
